The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations

Abstract

Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functional and mortality benefit to a select group of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known.

Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT).

Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis.

Measurements and main results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV(1) (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and room air arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively).

Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function.

Trial registration: ClinicalTrials.gov NCT00000606.

Figures

Figure 1.

Time to first exacerbation analysis performed during the year before enrollment in the National Emphysema Treatment Trial, where Day 365 corresponds to the day of study randomization (P = 0.85).

Figure 2.

(A) Time to exacerbation analysis in the 3 years after enrollment in the National Emphysema Treatment Trial. The surgical cohort experienced a statistically significant increase in the time to first exacerbation (P < 0.0001). (B) The same time to event analysis using all other ICD-9 discharge codes (nonexacerbation codes) (P = 0.31).

Figure 2.

(A) Time to exacerbation analysis in the 3 years after enrollment in the National Emphysema Treatment Trial. The surgical cohort experienced a statistically significant increase in the time to first exacerbation (P < 0.0001). (B) The same time to event analysis using all other ICD-9 discharge codes (nonexacerbation codes) (P = 0.31).

Figure 3.

Time to event analysis of surgical responders defined as 6-month improvement in FEV1 greater than 0.200 L and the surgical nonresponders defined as those with less than a 0.200-L improvement in FEV1 over the same time period.